Business Segments · Cost of Sales

Reportable Segment — Cost of Sales

Amgen Reportable Segment — Cost of Sales increased by 1.0% to $2.51B in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 12.1%, from $2.85B to $2.51B.

Analysis

StatementSegment
First reportedQ1 2024
Last reportedQ3 2025
Rolls up toTotal Cost of Revenue
Metric ID: amgn_segment_reportable_segment_cost_of_sales

Historical Data

6 periods
 Q1 '24Q2 '24Q3 '24Q1 '25Q2 '25Q3 '25
Value$2.81B$2.83B$2.85B$2.53B$2.48B$2.51B
QoQ Change—+0.4%+1.0%-11.4%-1.7%+1.0%
YoY Change———-10.2%-12.1%-12.1%
Range$2.48B – $2.85B
CAGR-8.8%
Avg YoY Growth-11.4%
Median YoY Growth-12.1%

Frequently Asked Questions

What is Amgen's reportable segment — cost of sales?
Amgen (AMGN) reported reportable segment — cost of sales of $2.51B in Q3 2025.
How has Amgen's reportable segment — cost of sales changed year-over-year?
Amgen's reportable segment — cost of sales decreased by 12.1% year-over-year, from $2.85B to $2.51B.

Cookie Preferences

We use cookies for analytics. See our Privacy and Cookie Policy.